Back to the main directory
EarningsReview / Equity
- Q3 2025 first take by BNP Paribas
- Tripod Technology Corp (3044 TT) by HSBC
- Sustainability Weekly 3-7 November 2025 by Oddo BHF
- ChemoMetec - Significant XM ramp-up cements the equity story by Danske Bank Equity Research
- Meds Apotek AB - Do take your Meds by Danske Bank Equity Research
- Consolidation overhang likely to persist; reiterate Underperform by BNP Paribas
- Resilient growth driven by innovative products by BNP Paribas
- Recall when adds used to grow? by BNP Paribas
- Q126 sales and 15 questions for management by BNP Paribas
- Upbeat sellside roundtable by BNP Paribas
- Small progress by BNP Paribas
- by BNP Paribas
- Swedish Orphan Biovitrum - Adding Tryngolza to our model, game-changer in sHTG by Danske Bank Equity Research
- The WSJ reports Visa and Mastercard are nearing historic merchant settlement by BNP Paribas
- Conference Guide by BNP Paribas
- Beat in EBITDA driven by cost rationalisation by BNP Paribas
- Banca Mediolanum - 3Q25 RESULTS BEAT: FLOWS MOMENTUM & DIVIDEND GROWTH by Equita Sim
- Container shipping: record-breaking order frenzy, Chinese exports, Ocean freight rates, Trade war, Airfreight rates, Aena, Getlink, IAG, Wizz Air, Vinci, ACS/ Ferrovial by BNP Paribas
- Q3 results: Getting what we wanted by BNP Paribas
- In-line Q3 with reiterated guidance: first take by BNP Paribas
- Results Flash - Q3 EBITDA beat slightly, strong FCF, but modest Q4 downside risk by BNP Paribas
- Daily News by BNP Paribas
- Analyst meeting feedback by BNP Paribas
- ALMIRALL: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- MercadoLibre (MELI US) by HSBC